Peled, Nir
Gillis, Roni
Kilickap, Saadettin
Froesch, Patrizia
Orlov, Sergei
Filippova, Elena
Demirci, Umut
Christopoulos, Petros
Cicin, Irfan
Basal, Fatma Bugdayci
Yilmaz, Cengiz
Fedor, Moiseenko
Korkmaz, Taner
Paydas, Semra
Gautschi, Oliver
Zirtiloglu, Alisan
Eralp, Yesim
Cinkir, Havva Yesil
Sezer, Ahmet
Erman, Mustafa
Tural, Deniz
Turna, Hande
Mazieres, Julien
Dudnik, Elizabeth
Reguart, Noemi
Camidge, David Ross
Ng, Terry L.
Şenler, Filiz Çay
Beypınar, İsmail
Yazılıtaş, Doğan
Demirkazık, Ahmet
Karaoğlu, Aziz
Okutur, Kerem
Coşkun, Hasan Şenol
Şendur, Mehmet Ali Nahit
Isikdogan, Abdurrahman
Cabuk, Devrim
Yumuk, Perran Fulden
Yıldız, Ibrahim
Kaplan, M. Ali
Özyılkan, Özgür
Öztop, İlhan
Olmez, Omer Fatih
Aydin, Kübra
Aydıner, Adnan
Meydan, Nezih
Grinberg, Roxana Denisa
Roisman, Laila C.
Funding for this research was provided by:
Pfizer (IIS 53234545)
This article is maintained by: Elsevier
Article Title: GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients
Journal Title: Lung Cancer
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.lungcan.2020.07.022
Content Type: article
Copyright: © 2020 Published by Elsevier B.V.